Thus, Roxadustat might be safe to use in diabetics with anemia of CKD and simultaneous diabetic retinopathy because Roxadustat does not require Müller cell HIF-2, the mediator of pathological angiogenesis, to induce protection of retinal vessels, and Roxadustat has a weak effect on Müller cell HIF-2α. The gene discussed is EPAS1; the disease is anemia.